CA2687786A1 - Combination of chk and parp inhibitors for the treatment of cancers - Google Patents

Combination of chk and parp inhibitors for the treatment of cancers Download PDF

Info

Publication number
CA2687786A1
CA2687786A1 CA2687786A CA2687786A CA2687786A1 CA 2687786 A1 CA2687786 A1 CA 2687786A1 CA 2687786 A CA2687786 A CA 2687786A CA 2687786 A CA2687786 A CA 2687786A CA 2687786 A1 CA2687786 A1 CA 2687786A1
Authority
CA
Canada
Prior art keywords
6alkyl
optionally substituted
cancer
aryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2687786A
Other languages
English (en)
French (fr)
Inventor
Mark James O'connor
Graeme Cameron Murray Smith
Sonya Zabludoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2687786A1 publication Critical patent/CA2687786A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2687786A 2007-05-25 2008-05-23 Combination of chk and parp inhibitors for the treatment of cancers Abandoned CA2687786A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94020307P 2007-05-25 2007-05-25
US60/940,203 2007-05-25
PCT/GB2008/050372 WO2008146035A1 (en) 2007-05-25 2008-05-23 Combination of chk and parp inhibitors for the treatment of cancers

Publications (1)

Publication Number Publication Date
CA2687786A1 true CA2687786A1 (en) 2008-12-04

Family

ID=39672970

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2687786A Abandoned CA2687786A1 (en) 2007-05-25 2008-05-23 Combination of chk and parp inhibitors for the treatment of cancers

Country Status (11)

Country Link
US (1) US20100249112A1 (enExample)
EP (1) EP2167086A1 (enExample)
JP (1) JP2010527981A (enExample)
KR (1) KR20100020981A (enExample)
CN (1) CN101743003A (enExample)
AU (1) AU2008256562A1 (enExample)
BR (1) BRPI0811059A2 (enExample)
CA (1) CA2687786A1 (enExample)
MX (1) MX2009012705A (enExample)
RU (1) RU2009147819A (enExample)
WO (1) WO2008146035A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010081778A1 (en) * 2009-01-17 2010-07-22 Universität Zürich Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer
WO2012014221A1 (en) 2010-07-27 2012-02-02 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1- carbonyl)benzyl)phthalazin-1(2h)-one derivatives as poly (adp-ribose) polymerase- 1 inhibitors
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
MX2015006780A (es) 2012-12-31 2015-08-06 Cadila Healthcare Ltd Derivados de ftalazin-1-(2h)-ona sustituida.
WO2017013237A1 (en) 2015-07-23 2017-01-26 Institut Curie Use of a combination of dbait molecule and parp inhibitors to treat cancer
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
MX2019012176A (es) 2017-04-10 2020-02-19 Sierra Oncology Inc Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
WO2019175132A1 (en) 2018-03-13 2019-09-19 Onxeo A dbait molecule against acquired resistance in the treatment of cancer
CA3095709A1 (en) 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN120441567A (zh) 2020-04-07 2025-08-08 Crt先锋基金有限公司 Chk1抑制剂的合成方法
CN112375070B (zh) * 2020-06-29 2023-03-28 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
WO2022000946A1 (zh) * 2020-06-29 2022-01-06 中国药科大学 含有酞嗪-1(2h)-酮结构的parp抑制剂、其制法及医药用途
WO2024261243A1 (en) 2023-06-21 2024-12-26 Hemispherian As Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) * 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
SG150548A1 (en) * 2003-12-01 2009-03-30 Kudos Pharm Ltd Dna damage repair inhibitors for treatment of cancer
JP2007517843A (ja) * 2004-01-05 2007-07-05 アストラゼネカ アクチボラグ Chk1阻害剤であるチオフェン誘導体
WO2006078503A2 (en) * 2005-01-07 2006-07-27 Arqule, Inc. Compositions for modulation of parp and methods for screening for same
WO2008020180A2 (en) * 2006-08-17 2008-02-21 Kudos Pharmaceuticals Limited Methods of increasing the sensitivity of cancer cells to dna damage

Also Published As

Publication number Publication date
AU2008256562A1 (en) 2008-12-04
RU2009147819A (ru) 2011-06-27
WO2008146035A1 (en) 2008-12-04
KR20100020981A (ko) 2010-02-23
JP2010527981A (ja) 2010-08-19
US20100249112A1 (en) 2010-09-30
MX2009012705A (es) 2009-12-08
BRPI0811059A2 (pt) 2017-05-09
EP2167086A1 (en) 2010-03-31
CN101743003A (zh) 2010-06-16

Similar Documents

Publication Publication Date Title
US20100249112A1 (en) Combination of chk and parp inhibitors for the treatment of cancers
AU2010364807B2 (en) Heterocyclic derivates, preparation processes and medical uses thereof
CA2517629C (en) Phthalazinone derivatives
ES2364140T3 (es) Derivados de ftalazinona.
CN102686591B (zh) 酞嗪酮类衍生物、其制备方法及其在医药上的应用
JP2009512671A (ja) 4−ヘテロアリールメチル置換されたフタラジノン誘導体
TW200900396A (en) Phthalazinone derivatives
KR20070057859A (ko) 4-헤테로아릴메틸 치환된 프탈라지논 유도체
AU2008313504A1 (en) Combination 059
CN102898377A (zh) 一类新型酞嗪酮衍生物及其用途
WO2022261220A1 (en) Proteolysis targeting chimeras and methods of use thereof
CA3078942A1 (en) Pyrrolotriazine compounds and methods of inhibiting tam kinases
US20040127504A1 (en) Benzimidazoles that are useful in treating sexual dysfunction
AU2008299721A1 (en) Phthalazinone derivatives
CN115381832A (zh) 癌症的治疗
CN110272419A (zh) 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
CN117384161A (zh) 靶向降解cdk蛋白的化合物及其应用
CN115836077B (zh) 氧杂氮杂螺环类衍生物、其制备方法及其在医药上的应用
EP3878841B1 (en) Indazole kinase inhibitor and use thereof
HK40083903A (en) Treatment of cancer
CN117777124A (zh) Parp选择性抑制剂
US20100240645A1 (en) Combination of checkponit kinase (chk) and telangiectasia mutated (atm) inhibitors for the treatment of cancer
HK40001545A (en) Treatment of cancer
HK40009984A (en) Erbb inhibitors and uses thereof
MX2008004913A (en) 4-heteroarymethyl substituted phthalazinone derivatives

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130523